ADVM - Adverum Biotechnologies Inc.

-

$undefined

N/A

(N/A)

Adverum Biotechnologies Inc. NASDAQ:ADVM Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.

Location: 800 Saginaw Drive, California, 94063, US | Website: adverum.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

77.29M

Cash

153.2M

Avg Qtr Burn

-21.39M

Short % of Float

12.75%

Insider Ownership

11.67%

Institutional Own.

94.02%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.